Received: 16 September 2022
Accepted: 28 February 2023
First Online: 7 April 2023
: Hirota N is an employee of Osaka Pharma Plan. Neither Okamura N nor Okada H has any interest in Osaka Pharma Plan. All researchers declare that they have no competing interests in relation to this study.
: This study was conducted in accordance with the Declaration of Helsinki. It was conducted after receiving approval from the Institutional Review Board of Mukogawa Women’s University (Approval No. 20–60). Prior to the implementation of this study, it was registered with the UMIN Clinical Trial Registration System (UMIN Trial ID: UMIN000042571). The patients’ informed consent to participate in this study was obtained via consent forms.
: Not applicable.